Tirzepatide
Mounjaro, Zepbound, LY3298176
A dual GLP-1 and GIP receptor agonist used for type 2 diabetes and obesity, enhancing insulin secretion, suppressing glucagon, and promoting weight loss.
Completed
PHASE1
NCT05978713
A Study of Tirzepatide (LY3298176) in Healthy Lactating Females
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE4
NCT05553093
Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes
Nanjing First Hospital, Nanjing Medical University
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT04235959
A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE4
NCT06803888
Bariatric Surgery vs. Semaglutide vs. Tirzepatide
Ali Aminian
INTERVENTIONAL
Updated Dec 15, 2025
Completed
NA
NCT06895408
Separate and Combined Extrapancreatic Effects of GIP and GLP-1
University Hospital, Gentofte, Copenhagen
INTERVENTIONAL
Updated Dec 15, 2025
Enrolling By Invitation
PHASE2, PHASE3
NCT06162715
GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial
Vanderbilt University Medical Center
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
PHASE1
NCT07095517
Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
Massachusetts General Hospital
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
NCT06790160
Study of Patients Being Treated With Anti-obesity Medication
Texas Tech University
OBSERVATIONAL
Updated Dec 15, 2025
Not Yet Recruiting
NCT07251803
GLP1 Fasting Status and Gastric Retention Using Gastric Ultrasound
Medical University of South Carolina
OBSERVATIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT06935838
Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV
University of Hawaii
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT06976853
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
Washington University School of Medicine
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
EARLY PHASE1
NCT06759701
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
M.D. Anderson Cancer Center
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT06221969
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE4
NCT05564039
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE4
NCT06374875
Fibrosis Lessens After Metabolic Surgery
Ali Aminian
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE1
NCT05822544
Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
OrsoBio, Inc
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE3
NCT06246799
Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
The University of Texas Health Science Center at San Antonio
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT05691712
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
NCT07262762
Spartina® (Tirzepatide) Effectiveness and Safety Evaluation
Cinnagen
OBSERVATIONAL
Updated Dec 15, 2025
Completed
NCT06761703
A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss
Amgen
OBSERVATIONAL
Updated Dec 15, 2025